*仅供医学专业人士阅读参考
ASCO大会备受关注的研究有哪些？
撰文 | 玖陆
2023年美国临床肿瘤学会（ASCO）会议将在美国时间6月2日-6日在芝加哥召开。作为全球规模最大的肿瘤领域学术会议，世界一流的肿瘤学专家齐聚一堂，将国际最前沿的临床肿瘤学研究成果和治疗技术分享给参会者。对于肿瘤学者，ASCO年会是绝对不容错过的学术交流盛会。
日前，摘要标题已公布。小编特此整理入选全体大会的研究，以飨读者。
胃肠道肿瘤领域治疗新进展荟萃
1、ATTRACTION-5:纳武利尤单抗联合化疗术后辅助治疗pStage III期胃癌/胃食管交界肿瘤的III期研究
ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer.
摘要：4000
讲者: Masanori Terashima, MD, PhD, FACS|Shizuoka Cancer Center, Devision of Gastric Surgery
2、围手术期特瑞普利单抗联合SOX/XELOX化疗vs单独SOX/XELOX化疗治疗胃癌/胃食管交界肿瘤疗效：一项前瞻性，随机，开放标签，II期试验
Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer:Results from a prospective, randomized, open-label, phase II trial.
摘要：4001
讲者：Shuqiang Yuan,MD|State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Sun Yat-sen University
3、阿替利珠单抗+贝伐珠单抗vs主动监测，在切除或消融后疾病复发风险高的肝细胞癌（HCC）患者的比较，来自IMbrave050 III期试验有效性、安全性和患者报告结局结果。
Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) +bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation.
摘要：4002
讲者：Masatoshi Kudo, MD, PhD|Kindai University Hospital
4、帕博利珠单抗联合吉西他滨和顺铂vs安慰剂治疗晚期胆道癌（BTC），来自KEYNOTE-966 III期研究的健康相关生活质量（HRQoL）结果
Health-related quality of life (HRQoL) in the phase 3 KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) versus placebo plus gem/cis for advanced biliary tract cancer (BTC) .
摘要：4003
讲者：Changhoon Yoo, MD, PhD|Asan Medical Center, University of Ulsan College of Medicine
5、在不可切除肝癌HIMALAYA III期研究中，Tremelimumab (T) +度伐利珠单抗 (D) 的免疫不良反应的发生率
Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC) .
摘要：4004
讲者：George Lau, MD|Humanity and Health Clinical Trial Center, Humanity and Health Medical Group
6、可切除胰腺头癌的短程新辅助治疗FOLFIRINOX与前期手术的比较：一项多中心随机II期试验（NORPACT-1）。
Short-course neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer: A multicenter randomized phase-II trial (NORPACT-1) .
摘要：LBA4005
讲者：Knut Jørgen Labori, MD PhD|Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo
7、伊立替康+5-氟尿嘧啶/亚叶酸钙+奥沙利铂（NALIRIFOX）vs白蛋白结合型紫杉醇+吉西他滨在初治转移性胰腺导管腺癌（mPDAC）的疗效：NAPOLI III期试验12个月和18个月生存率
Liposomal irinotecan+5-fluorouracil/leucovorin+oxaliplatin (NALIRIFOX) versus nab-paclitaxel+gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) : 12-and 18-month survival rates from the phase 3 NAPOLI 3 trial .
摘要：4006
讲者：Eileen Mary O"Reilly, MD|Memorial Sloan Kettering Cancer Center
8、妥卡替尼和曲妥珠单抗用于既往治疗HER2+转移性胆道癌：一项2期篮子研究（SGNTUC-019）
Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019) : A phase 2 basket study.
摘要：4007
讲者：Yoshiaki Nakamura, MD, PhD|National Cancer Center Hospital Japan East
9、HERIZON-BTC-01关键2b期研究：Zanidatamab治疗既往治疗失败的HER2扩增胆道癌症（BTC）。
Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2amplified biliary tract cancer (BTC) .
摘要：4008
讲者：Shubham Pant, MD|MD Anderson Cancer Center
晚期结直肠癌的最佳治疗“拍档”
1、FOLFOXIRI联合贝伐珠单抗和阿替利珠单抗治疗不可切除的转移性结直肠癌（mCRC）：AtezoTRIBE II期随机研究结果更新和总生存期。
FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable metastatic colorectal cancer (mCRC) : Updated and overall survival results of the phase II randomized AtezoTRIBE study.
摘要：3500
讲者：Carlotta Antoniotti,MD,PhD|Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa&Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana
2、T-DXd治疗HER多表达/扩增（HER2+）转移性结直肠癌：多中心、随机、III期DESTINY-CRC02研究的主要结果。
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC) : Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.
摘要：3501
讲者：Kanwal Pratap Singh Raghav, MBBS|The University of Texas MD Anderson Cancer Center
3、新辅助化疗和标准治疗在局部晚期结肠癌患者中疗效的III期随机临床试验：NeoCol试验
Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial.
摘要：LBA3503
讲者：Lars Henrik Jensen, MD, PhD|Danish Colorectal Cancer Center South, University Hospital of Southern Denmark, Vejle Hospital
4、mFOLFIRINOX的新辅助治疗vs术前放化疗治疗局部晚期直肠癌患者：PRODIGE 23 III期7年研究结果（UNICANCER GI）
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial.
摘要：LBA3504
讲者：Thierry Conroy, MD|Institut de Cancérologie de Lorraine
5、新辅助治疗方案mFOLFOX6联合或不联合放疗vs氟尿嘧啶和放疗治疗局部晚期直肠癌的长期结局：一项多中心、随机III期试验。
Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial.
摘要：3505
讲者：张剑威|中山大学附属第六医院
6、SCRUM-Japan GOZILA研究中的NeoRAS野生型转移性结直肠癌。
NeoRAS wild-type metastatic colorectal cancer in the SCRUM-Japan GOZILA study.
摘要：3506
讲者：Hiroki Osumi, MD, PhD|Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research
7、FIRE-4 III期研究（AIO KRK-0114）：液体活检结果对FOLFIRI/西妥昔单抗首次治疗RAS-WT mCRC患者疗效的影响。
Phase III FIRE-4 study (AIO KRK-0114) : Influence of baseline liquid biopsy results in first-line treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC.
摘要：3507
讲者：Sebastian Stintzing, MD|Medical Department, Division of Hematology, Oncology,and Cancer Immunology (CCM) , CharitéUniversitätsmedizin Berlin
8、帕尼单抗在左半、MSS/MSI-L和RAS/BRAF WT结直肠癌患者中的疗效：PARADIGM III期生物标志物研究。
Efficacy of panitumumab in patients with left-sided disease,MSS/MSI-L, and RAS/BRAF WT: A biomarker study of the phase III PARADIGM trial.
摘要：3508
讲者：Kentaro Yamazaki, MD, PhD|Division of Gastrointestinal Oncology, Shizuoka Cancer Center
肝胆癌新靶点药物亮相！
1、ReFocus研究剂量递增结果更新，高选择性FGFR2抑制剂RLY-4008在胆管癌和其他实体瘤中的首次人体研究
Updated dose escalation results for ReFocus,a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors.
摘要：4009
讲者：Mitesh J. Borad, MD|Mayo Clinic Arizona
2、MORPHEUS-肝脏研究：Tiragolumab联合阿替利珠单抗和贝伐珠单抗治疗不可切除的局部晚期或转移性肝细胞癌（uHCC）的Ib/II期随机研究。
Results from the MORPHEUS-liver study:Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab(bev)in patients with unresectable,locally advanced or metastatic hepatocellular carcinoma (uHCC) .
摘要：4010
讲者：Richard S. Finn, MD|University of California Los Angeles
3、nanvuranlat治疗经治、晚期、难治性胆道癌（BTC）的一项双盲、安慰剂对照Ph2期研究的亚组分析：LAT1表达高和nanvuranlat治疗有效的患者。
Subgroup analysis of double-blind,placebo-controlled Ph.2 study of nanvuranlat in treatment of pre-treated, advanced, refractory biliary tract cancer (BTC) : Patients with high LAT1 expression and response to nanvuranlat.
摘要：4011
讲者：Masafumi Ikeda, MD, PhD|Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East
小结
在胃肠道肿瘤中，本次ASCO大会公布了胃癌、肝癌、胆道癌、胰腺癌等最新研究结果，其中包括对于新辅助化疗和标准治疗在局部晚期结直肠癌的晚期不可以切除结直肠的NeoCol III研究结果公布，也为结直肠癌新辅助治疗提供重要的临床用药参考。这些研究能否突破目前胃肠道肿瘤治疗瓶颈，更是值得期待。
为了向临床医生传递肿瘤领域的新观念、新知识和新技术，鼓励和支持我国临床肿瘤医学研究与创新，医学界传媒将紧跟ASCO会议学术热点，通过线下参会、国内外专家交流、大会解读报道、大咖观点分享等形式来全面展现会议最新内容。
精彩资讯等你来
责任编辑： Sheep
*医学界力求其发表内容专业、可靠，但不对内容的准确性做出承诺；请相关各方在采用或以此作为决策依据时另行核查。
